Relevant bibliographies by topics / Intradermal Injections

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers

Academic literature on the topic 'Intradermal Injections'

Author: Grafiati
Published: 4 June 2021
Last updated: 29 July 2024

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Intradermal Injections.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Intradermal Injections"

1

Koloshein, N. A., M. G. Ryabkov, M. N. Egorikhina, L. B. Timofeeva, P. V. Peretyagin, and I. Yu Arefev. "Comparison of the Effectiveness of Methods for Obtaining and Application the Stromal-Vascular Fraction of Adipose Tissue in an Experimental Model of a Donor Wound in Burns." Ural Medical Journal 23, no. 1 (March 6, 2024): 24–36. http://dx.doi.org/10.52420/2071-5943-2024-23-1-24-36.

Full text
Abstract:
Introduction. The optimal method of obtaining and application a stromal-vascular fraction (SVF) of adipose tissue in the treatment of donor wounds in burned patients has not been determined.Objective — to compare the effectiveness of the stromal-vascular fraction of adipose tissue in the treatment of donor wounds, depending on the method of obtaining (mechanical and enzymatic) and the injection (subdermal, intradermal) into the tissue.Material and methods. Wistar rats (n = 30) were divided into 2 investigated groups: in the first group (eSVF) enzymatic processing of adipose tissue (n = 10) was used, in the second group (mSVF) mechanical processing was used (n = 10). Another 10 rats were used as adipose tissue donors’ group. A deep burn was created in all animals, and after 4 days two more donor wounds were created by taking a split thickness skin autograft: the stromal-vascular fraction was injected intradermally into one of the wounds, subdermally into the other. After 14 days, the area of epithelialization, the microcirculation index and the histological microstructure of the skin were evaluated.Results. The proportion of completely epithelized donor wounds in the eSVF-group was 85 %, in the mSVF-group — 55 % (p < 0.05). The index of microcirculation significantly decreased after intradermal injections in the eSVF-group (p < 0.01), and after subdermal injections — in the mSVF-group (p < 0.05). According to histomorphometry, with intradermal injections of eSVF, the thickness of the epidermis and the layer of granulation tissue is less than in the mSVF group (p < 0.01). At the same time, the relative density of collagen fibers in the granulation tissue was significantly higher after the injections of eSVF than after mSVF (p < 0.01). Comparison of injections of the stromal-vascular fraction showed: no significant differences were found when using eSVF; when using mSVF, the subdermal injections are preferable, since it was accompanied by a significantly lower thickness of granulation tissue (p < 0.01).Conclusions. The enzymatically obtained stromal-vascular fraction of adipose tissue has advantages over the mechanically obtained one: the efficiency of eSVF is equally high when used with intradermally and subdermally injections, which are confirmed by the structure and blood circulation in the newly formed skin. When using mSVF, intradermal injections are the least effective, and subdermal injections are accompanied by a moderately pronounced positive dynamic in the microstructure of the skin of donor wounds.
APA, Harvard, Vancouver, ISO, and other styles
2

Hsu, Chao Chin, Isabel Hsu, Hui Hua Chang, Rosie Hsu, and Sonam Dorjee. "Extended Injection Intervals of Gonadotropins by Intradermal Administration in IVF Treatment." Journal of Clinical Endocrinology & Metabolism 107, no. 2 (October 3, 2021): e716-e733. http://dx.doi.org/10.1210/clinem/dgab709.

Full text
Abstract:
Abstract Context Gonadotropins can be administered every 5 days under intradermal injection in in vitro fertilization (IVF) treatment. Objective To explore the effectiveness of intradermal injection of recombinant human FSH (rhFSH) for women undergoing IVF. Methods Women who received their first IVF treatment enrolled in this prospective intervention in 2018. All women received a bolus of 900 IU rhFSH intradermally at day 2 of the treatment cycle followed by additional dosage of rhFSH at day 7 and/or day 10. The main outcome measures included the total dose of rhFSH and number of injections required, sequential serum FSH level detected, and number of mature oocytes retrieved. Results Seventy women completed the study. On average, 2.31 ± 0.73 injections and 1662 ± 397 IU of rhFSH were administered. While the baseline FSH level was 5.6 ± 2.2 IU/L, the serum concentrations of FSH after rhFSH administration were 35.3 ± 7.0 on the first day (24 hours) and 10.7 ± 3.7 IU/L on the fifth day (120 hours). A total of 10.5 ± 6.6 mature oocytes were retrieved, resulting in 7.3 ± 5.1 pronuclear embryos; 1.8 ± 0.6 embryos were transferred to the uterus. Our findings resulted in 72% fertilization, 91% cleavage, 31% implantation, and 36% live birth rates. Although fewer larger follicles were found, noninferiority results were noted in the mature oocytes retrieved, good embryos available, and clinical pregnancy rate compared with those received conventional daily subcutaneous rhFSH administration. Conclusion Intradermal administration of rhFSH, with a smaller dose of rhFSH and fewer injections, may achieve the goal of a cost-effective and more patient-friendly regimen.
APA, Harvard, Vancouver, ISO, and other styles
3

Molinari, J. F., W. R. Moore, J. Clark, R. Tanaka, J. H. Butterfield, and W. M. Abraham. "Role of tryptase in immediate cutaneous responses in allergic sheep." Journal of Applied Physiology 79, no. 6 (December 1, 1995): 1966–70. http://dx.doi.org/10.1152/jappl.1995.79.6.1966.

Full text
Abstract:
In this study, we used a specific tryptase inhibitor, APC-366 [N-(1-hydroxy-2-napthoyl)-L-arginyl-L- prolinamide hydrochloride] to investigate the effect of intradermally administered tryptase and tryptase released by antigen challenge on the immediate cutaneous reaction (ICR) in allergic sheep. The surface areas of cutaneous wheals produced by intradermal injections (0.05 ml) of 1 and 10 ng tryptase alone, tryptase combined with 3 U heparin (tryptase-heparin), or Ascaris suum antigen (10(-5) dilution) with or without pretreatment with APC-366 (1 mg/ml) were measured at 20 and 60 min after challenge. Intradermal injections of 1 and 10 ng tryptase alone (n = 7) produced an ICR of < or = 20% of that obtained after injection of histamine (5% wt/vol). Intradermal injection of tryptase-heparin (n = 7), however, resulted in 50 (1 ng) and 82% (10 ng) of the ICR to histamine (both, P < 0.05 vs. tryptase alone). APC-366 inhibited (P < 0.05) the ICR to 1 and 10 ng tryptase-heparin by > or = 70% at all times (n = 8) but had no effect on the histamine-induced ICR (n = 3). A combination of the histamine H1 antagonist chlorpheniramine (2 mg/kg iv) and the H2 antagonist metiamide (3 mg/kg iv) given 40 min before challenge (n = 8) inhibited the response to 1 and 10 ng tryptase-heparin by 42 and 62% at 20 min and by 96 and 86% at 60 min, respectively (all, P < 0.05). APC-366 also blocked the ICR to A. suum antigen by 68% (P < 0.05) in nine sheep. These results indicate that intradermal injection of tryptase-heparin can induce an ICR. This ICR can be inhibited by APC-366 or a combination of the histamine H1 and H2 antagonists, suggesting that the tryptase response is mediated by histamine. APC-366 also blocks the mast cell-mediated ICR to intradermally injected A. suum antigen. Collectively, these results suggest that tryptase may modulate mast cell histamine release.
APA, Harvard, Vancouver, ISO, and other styles
4

Pearson, Jason, Renato Leon, Haley Starr, Sujung Jun Kim, Jonathan E. Fogle, and Frane Banovic. "Establishment of an Intradermal Canine IL-31-Induced Pruritus Model to Evaluate Therapeutic Candidates in Atopic Dermatitis." Veterinary Sciences 10, no. 5 (May 4, 2023): 329. http://dx.doi.org/10.3390/vetsci10050329.

Full text
Abstract:
Pruritic models in healthy dogs utilizing intravenous administration of interleukin 31 (IL-31) bypass the “natural” itch sensation in AD, which is initiated by pruriceptive primary afferent neurons in the skin. This study aimed to evaluate the immediate/delayed pruritus responses and the pruritic behaviors observed in an intradermal IL-31-induced pruritic model of healthy dogs and the anti-pruritic effect of oclacitinib on said model. In Phase 1, all the dogs were randomized and video-recorded for 300 min after intradermal canine recombinant IL-31 injections (1.75 µg/kg) and vehicle (phosphate-buffered saline) injections. In Phase 2, all the dogs received oral oclacitinib (0.4–0.6 mg/kg, twice daily for 4 consecutive days and once daily on day 5), with the intradermal IL-31 injection performed on day 5. Two blinded investigators reviewed the pruritic behaviors in all the video recordings. Intradermal IL-31 administration to healthy dogs caused a significant increase in the total (p = 0.0052) and local (p = 0.0003) seconds of pruritic behavior compared to the vehicle control. Oral oclacitinib administration significantly reduced the total (p = 0.0011) and local (p = 0.0156) intradermal IL-31-induced pruritic seconds; there was no significant difference in pruritic seconds between the vehicle and oclacitinib within the IL-31 groups. Significant delayed pruritic responses at 150–300 min after IL-31 injections were observed, and intradermal IL-31 failed to induce acute itch (first 30 min). Intradermal injection of IL-31 induces delayed itch responses in dogs that are diminished by the effect of oclacitinib, an oral JAK inhibitor.
APA, Harvard, Vancouver, ISO, and other styles
5

Oh, Seung Min, Yongkoo Lee, Jae Hyuk Lee, and Myungjune Oh. "Investigating the Mechanisms of Intradermal Injection for Easier “Skin Booster” Treatment: A Fluid Mechanics Approach to Determine Optimal Delivery Method." Plastic and Reconstructive Surgery - Global Open 12, no. 4 (April 2024): e5723. http://dx.doi.org/10.1097/gox.0000000000005723.

Full text
Abstract:
Background: The use of “skin boosters” for rejuvenating aged skin is widely used. However, the accurate injection of the skin booster into the dermal layer remains a challenge due to the density of the dermis. The purpose of this study was to investigate the optimal mechanical variables of delivery that enabled correct targeting of the product to the dermis for optimal results. Methods: We investigated the impact of mechanical variables (syringe diameter, needle diameter and length, and viscosity of the skin booster) on the force required for intradermal injection in porcine skin. The correlation between these variables and the injection force was examined as well. Results: The results show that smaller syringe diameters, larger needle diameters, shorter needle lengths, and lower viscosity of the skin boosters reduce the injection force needed for intradermal injections. Conclusions: During the administration of skin booster injections, clinicians should take into account optimal conditions that facilitate intradermal injections, thus maximizing rejuvenating outcomes. Furthermore, manufacturers of skin boosters should formulate the products with decreased viscosity and provide the product in conjunction with appropriate needles and syringes, designed to optimize ease of injection.
APA, Harvard, Vancouver, ISO, and other styles
6

Freed, D. L. J., C. Chattopadhyay, and I. Gupta. "Intradermal Salicylate Injections for Fibromyalgia." Journal of Orthopaedic Medicine 23, no. 1 (January 2001): 12–15. http://dx.doi.org/10.1080/1355297x.2001.11736123.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Babadjouni, Arash, Celine H. Phong, Jodie Raffi, and Natasha A. Mesinkovska. "Turning Down the Fire: The Role of Botulinum Toxin Microdroplets in Refractory Rosacea Erythema." SKIN The Journal of Cutaneous Medicine 6, no. 5 (September 12, 2022): 437–40. http://dx.doi.org/10.25251/skin.6.5.16.

Full text
Abstract:
Introduction: Dermal “micro-injections" of botulinum toxin A (BTX-A) treatment can improve facial flushing and erythema in patients with refractory rosacea. We present a case of a patient with longstanding papulo-pustular rosacea with flushing, refractory to laser, topical and systemic therapies, where intradermal microdroplet BTX-A injections successfully controlled erythema and flushing. Case Description: A 49-year-old White female with a 4-year history of refractory papulo-pustular rosacea presented with bright, central facial erythema and telangiectasias after failing multiple 595 nm pulsed dye laser, topical (azelaic acid 15% gel, 0.025% tretinoin cream, and metrocream 0.75%) and systemic (isotretinoin 20 mg daily, spironolactone 25 mg daily and doxycycline 100 mg twice daily for 14 days) treatments. At treatment 1, 20 U of BTX-A was injected intradermally (0.05 mL of 1.25 IU/0.1 mL per microdroplet) to erythematous lesion. Treatment 2 was performed at her 4 week follow-up were we administer 15 U of BTX-A intradermally (0.05 mL of 1.25 IU/0.1 mL per microdroplet) . The patient was seen 4, 8, and 16 weeks after her second treatment were no BTX-A was administered due to a significant reduction in erythema and lasting results. Discussion: Significant clinical improvement and patient satisfaction was achieved. No adverse events were reported after treatment aside from mild, localized injection site pain during the procedure. BTX-A administered as intradermal microdroplet injects can be a safe and efficacious option in the treatment of refractory rosacea erythema. Microbotox may be an effective adjunct, especially when topical and systemic therapies have failed.
APA, Harvard, Vancouver, ISO, and other styles
8

Bond, Matthew. "Intradermal Injections for Pox Eye Lesions." Journal of the Association of Avian Veterinarians 3, no. 3 (1989): 132. http://dx.doi.org/10.2307/30134019.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Uren, Roger, Chris Commens, and Robert Howman‐Giles. "Intradermal injections: a potential health hazard?" Medical Journal of Australia 161, no. 3 (August 1994): 226. http://dx.doi.org/10.5694/j.1326-5377.1994.tb127393.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Miljkovic, B., L. Peric, and M. Velhner. "Interdigital skin test for evaluation of delayed hypersensitivity and monitoring cell-mediated immune responses in chickens." Biotehnologija u stocarstvu 23, no. 5-6-2 (2007): 223–28. http://dx.doi.org/10.2298/bah0702223m.

Full text
Abstract:
A skin test to assess cell mediated delayed hypersensitivity (DH) used to evaluated immune response of chickens. Results of many study indicated, that skin testing is especially useful as a simple in vivo screening to evaluate normal and suppressed T-cell mediated DH. Chickens were sensitized with using mitogens, B and T-cell dependent antigen by intradermal injection. The most feathered skin of chickens is too thin for adequate intradermal injections, so the wattle is the standard site for skin testing, however, in younger than 2 or 3 weeks old chickens, the wattle is undeveloped and intradermal injection and measurement of response are difficult. A simple interdigital skin used by many of the authors. Skin swelling response and DH reaction were measured in mm before injections and after. The skin test and DH in vivo results edemas-initiating characteristics of sensitizing agents, which increase in skin thickness detectable after 4- 6 hours of application. Many of investigation results suggests that healthy chickens are able to have strong immune response and support the concept that some changes in the cell-mediated immune response and other pathogens may potentially affect immune response.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Intradermal Injections"

1

Liu, John (John Hsiao-Yung). "Intradermal needle-free powdered drug injection." Thesis, Massachusetts Institute of Technology, 2012. http://hdl.handle.net/1721.1/74993.

Full text
Abstract:
Thesis (S.M.)--Massachusetts Institute of Technology, Dept. of Mechanical Engineering, 2012.
Cataloged from PDF version of thesis.
Includes bibliographical references (p. 65-67).
This thesis presents a new method for needle-free powdered drug injection. The design, construction, and testing of a bench-top helium-powered device capable of delivering powder to controllable depths within the dermis is presented. This device uses a jet of gas undergoing choked flow to entrain powder and subsequently penetrates through the skin for delivery of the powder. Different nozzle designs and orifice geometries are also explored. In vitro injection of polymer beads (1-5 [mu]im in diameter) into porcine tissue demonstrate the device's capability of drug delivery to depths of 260 to 5000 [mu]m. The jet parameters of nozzle orifice diameter and applied pressure are shown to affect injection depth, shape, and success rate. The presented device has the potential to be implemented with stabilized formulations of vaccines to address the cold chain problem-the cost and risk of transporting temperature sensitive vaccines to developing countries.
by John Liu.
S.M.
APA, Harvard, Vancouver, ISO, and other styles
2

Ferguson, Peter Charles. "Intradermal injection of autologus dermal fibroblasts improves wound healing in irradiated skin." Thesis, National Library of Canada = Bibliothèque nationale du Canada, 1998. http://www.collectionscanada.ca/obj/s4/f2/dsk1/tape11/PQDD_0005/MQ40803.pdf.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Tarantola, Arnaud. "Epidemiology as a tool to improve prevention of human rabies : local and global health implications of postexposure prophylaxis data, Institut Pasteur du Cambodge, 2003-2014." Thesis, Sorbonne Paris Cité, 2018. http://www.theses.fr/2018USPCC031/document.

Full text
Abstract:
La rage entraîne plus de 60,000 décès par an dans le Monde, dont 800 au Cambodge, pays fortement endémique pour la rage canine.La mort survient dans près de 100% des cas de rage, maladie évitable dans presque 100% des cas par l’accès à une prophylaxie post-exposition (PPE) antirabique adéquate et en temps utile. L’amélioration de l’accès à une PPE dans les zones rurales des pays endémiques permettra d’épargner des vies humaines à court terme. Cette thèse en épidémiologie a tiré parti des données collectées auprès des patients consultant au centre antirabique et les chiens testés à l’Institut Pasteur du Cambodge (IPC), Phnom Penh. Suite à un bilan épidémiologique de la situation et des obstacles auxquels sont confrontés les patients cherchant à accéder à la PPE adéquate et en temps utile, elle vise à contribuer à améliorer 1/ l’accès géographique et 2/ l’accès financier à une PPE pour les populations rurales du Cambodge. Nous avons développé une stratégie originale d’identification des poches de populations à haut risque d’incomplétude vaccinale après une exposition potentielle à la rage. Ceci devrait permettre d’améliorer l’accès géographique à la PPE et se concrétiser par l’ouverture en Juillet 2018 d’un centre périphérique de prévention de la rage dans l’Ouest du Cambodge. Cette stratégie d’identification de difficultés d’accès aux soins est applicable à d’autres thématiques de santé, sous certaines conditions. Notre rappel des patients et l’analyse des décès par rage parmi les patients n’ayant pas complété de leur propre chef le protocole PPE de 4 sessions intradermales sur 1 mois ne permettent pas de mettre en évidence une différence de mortalité par rage parmi les patients n’ayant reçu que 3 sessions sur 1 semaine, par rapport à au moins 4 sessions/1mois. Le raccourcissement du protocole à 1 semaine permet de réduire les coûts directs et indirects et l’absence de revenus pendant la durée du traitement en capitale. La mise en place de ce protocole doit s’accompagner d’un suivi d’au moins 6 mois des patients après leur prise en charge initiale. L’ensemble de ces travaux a des implications qui dépassent le cadre du Cambodge: Dans ses recommandations d’Avril 2018, l’OMS recommande désormais ce nouveau protocole IPC– le premier protocole PPE antirabique abrégé à 1 semaine
Rabies causes more than 60,000 deaths worldwide each year, including 800 in Cambodia, where canine-mediated rabies virus circulates. Death occurs in nearly 100% of rabies cases, a disease which is nearly 100% avoidable by timely and adequate rabies post-exposure prophylaxis (PEP). Improving access to PEP in rural areas of endemic countries will spare human lives in the short term. This epidemiology PhD used the data collected in patients referred to the rabies prevention clinic and tested dogs at Institut Pasteur du Cambodge (IPC), Phnom Penh. After a baseline assessment of access to and obstacles to access timely and adequate PEP in Cambodia, this PhD aims to contribute to improving: 1/ geographical access and 2/ financial access to PEP for rural populations in Cambodia. We developed an original strategy to identify populations with a high risk of PEP noncompletion after a bite by a potentially rabid dog. This should help improve geographical access to PEP following the implementation in July 2018 of a peripheral rabies prevention center in Western Cambodia. This strategy can be applied to identify difficulties in accessing health services relevant to other health issues, under certain conditions. After patient callback and analysis of rabies deaths among those who did and did not complete the 4-sessions/1-month intradermal PEP regimen of their own accord, we were unable to demonstrate a difference in rabies mortality among patients who only received 3 vaccine sessions over the first week compared to those receiving at least 4 sessions/one month. Abridging the protocol to one week would reduce direct and indirect costs and the loss of income during PEP in the Capital. The adoption of this abridged regimen must be associated with a strengthened clinical monitoring system for at least 6 months following patients’ initial PEP.The work presented in this PhD has implications which reach beyond Cambodia: WHO recommends this new IPC regimen – the first approved one-week, abridged rabies PEP regimen – in its April 2018 guidelines
APA, Harvard, Vancouver, ISO, and other styles
4

Ganier, Clarisse. "Potentiel thérapeutique des cellules stromales mésenchymateuses dans l'épidermolyse bulleuse dystrophique récessive Intradermal injection of bone marrow-MSCs corrects recessive dystrophic epidermolysis bullosa in a xenograft model Intradermal injection of human umbilical cord-MSCs shows less efficacy than bone marrow-MSCs to correct recessive dystrophic epidermolysis bullosa in a xenograft model." Thesis, Sorbonne Paris Cité, 2018. https://wo.app.u-paris.fr/cgi-bin/WebObjects/TheseWeb.woa/wa/show?t=2117&f=15515.

Full text
Abstract:
L'épidermolyse bulleuse dystrophique récessive (EBDR) est une maladie génétique cutanée due à des mutations de perte de fonction du gène COL7A1 codant pour le collagène VII. Le collagène VII forme les fibres d'ancrage, structures essentielles pour l'adhésion de l'épiderme au derme sous-jacent. Les patients EBDR développent dès la naissance, des décollements bulleux de la peau et des muqueuses responsables de plaies chroniques et de graves complications locales et systémiques. La survenue de carcinomes épidermoïdes cutanés agressifs reste la première cause de décès. Il n'existe pas de traitement à ce jour. Les cellules stromales mésenchymateuses (CSM) sont des cellules multipotentes, isolées à partir de tissus adultes (moelle osseuse, tissu adipeux) ou de tissus périnataux (cordon ombilical). Des travaux antérieurs ont montré que les injections locales et systémiques de CSM issues de la moelle osseuse (CSM-MO) allogéniques ont un potentiel pour réduire l'inflammation cutanée et améliorer la cicatrisation des plaies chez les patients EBDR. Ces améliorations cliniques sont cependant transitoires et les mécanismes d'action des CSM-MO dans l'EBDR ainsi que leur durée de vie après injection sont mal connus. Les CSM-MO pourraient agir via leurs propriétés immunomodulatrices, anti-fibrotiques, pro-angiogéniques, par un effet paracrine permettant l'expression de collagène VII endogène et/ou la sécrétion de collagène VII par les CSM-MO injectées. L'objectif de cette thèse a été d'étudier le potentiel thérapeutique des CSM dans des modèles précliniques de l'EBDR. Nous avons tout d'abord montré que les CSM-MO expriment une quantité d'ARNm de COL7A1 et de collagène VII comparable aux fibroblastes dermiques sains en culture. Nous avons ensuite évalué la capacité des CSM-MO humaines à survivre et produire du collagène VII à la jonction dermo-épidermique (JDE) à long terme après une injection locale dans des peaux équivalentes humaines EBDR greffées sur souris nude. L'injection intradermique (ID) de CSM-MO in vivo a permis de restaurer l'expression du collagène VII ainsi que la formation de fibres d'ancrage à la JDE jusqu'à 6 mois après l'injection. Les CSM-MO sont retrouvées dans la peau équivalente jusqu'à 4 mois après l'injection. Ces résultats montrent qu'une injection ID unique de CSM-MO in vivo permet de rétablir une production prolongée de collagène VII synthétisé par les cellules injectées et d'améliorer l'adhésion dermo-épidermique de la peau équivalente EBDR. Nous avons ensuite comparé l'efficacité des CSM issues de la gelée de Wharton de cordon ombilicaux (CSM-CO) humains aux CSM-MO suivant la même méthodologie que précédemment. Les CSM-CO expriment en culture une quantité d'ARNm de COL7A1 et de collagène VII supérieures aux CSM-MO et fibroblastes dermiques sains. Une injection unique ID de CSM-CO dans la peau EBDR équivalente greffée permet de rétablir une faible expression de collagène VII jusqu'à 4 mois après l'injection. Les CSM-CO sont détectées dans la peau équivalente jusqu'à 2 mois après l'injection. Ces données montrent que les CSM-CO ont une capacité moindre à restaurer l'expression du collagène VII à la JDE comparativement aux CSM-MO injectées dans le même modèle de xénogreffes EBDR. Ces résultats ouvrent la perspective d'une thérapie génique ex vivo utilisant des CSM-MO murines Col7a1-/-. Les souris Col7a1-/- reproduisent les lésions cutanées et muqueuses observées chez les patients EBDR. L'espérance de vie de ces animaux est très réduite. Les CSM-MO murines Col7a1-/- transduites en culture à l'aide d'un vecteur rétroviral SIN exprimant COL7A1 produisent en moyenne 30 fois plus de collagène VII que les CSM-MO murines WT. Des expériences in vivo sont nécessaires pour déterminer si l'injection de CSM-MO génétiquement corrigées ont le potentiel de traiter des lésions cutanées et muqueuses, pour définir la dose optimale et la durée de l'effet chez l'animal. Ceci constituerait une étape importante vers la clinique
Recessive dystrophic epidermolysis bullosa (RDEB) is a severe skin disease caused by loss-of-function mutations in COL7A1 encoding type VII collagen. Type VII collagen forms anchoring fibrils which are essential structures for dermal-epidermal adherence. Patients with RDEB suffer since birth from skin and mucosal blistering and develop severe complications. The development of aggressive squamous cell carcinomas is the first cause of demise of these young patients. To date, there is no treatment. Mesenchymal stromal cells (MSC) are multipotent cells, isolated from adult tissue (bone marrow, adipose tissue) or perinatal tissue (umbilical cord). Previous works have shown that local and systemic injections of allogeneic bone marrow-derived MSC (BM-MSC) have a potential to reduce skin inflammation and to improve wound healing in RDEB patients. However, clinical improvement was transient and the mechanisms of action of BM-MSC in RDEB and also their survival after injection are still poorly understood. BM-MSC could act through immunomodulation, anti-fibrotic and angiogenic proprieties, paracrine effects leading to type VII collagen production in the host tissues and/or type VII collagen secretion by injected BM-MSC. The aim of our work was to study the therapeutic potential of MSC for RDEB in preclinical models. We first showed that BM-MSC produce COL7A1 mRNA and type VII collagen levels comparable to healthy dermal fibroblasts in culture. We then assessed the long-term capacity of human BM-MSC to survive, produce and deposit type VII collagen at the dermal-epidermal junction (DEJ) after local injection in human RDEB skin equivalents transplanted onto nude mice. In vivo intradermal (ID) injection of a single dose of human BM-MSC led to the production and deposition of human type VII collagen at the DEJ and allowed anchoring fibrils formation for at least six months post-injection. Injected human BM-MSC were found in the skin at least four months post-injection. These data show that intradermally injected human BM-MSC have the potential to improve dermal-epidermal adhesion of RDEB skin equivalents through sustained deposit of type VII collagen molecules and subsequent anchoring fibrils formation. We then compared the efficacy of human Umbilical Cord Wharton's Jelly-MSC (UC-MSC) with BM-MSC using the same methodology as previously described. UC-MSC showed in vitro a significantly higher amount of COL7A1 mRNA and type VII collagen compared to BM-MSC and healthy dermal fibroblasts in culture. ID injection of a single dose of UC-MSC in vivo led to the production and deposition of low levels of human type VII collagen at the DEJ for four months post-injection. Injected human UC-MSC were found in the skin two months post-injection. These data disclosed a lower efficacy of UC-MSC to restore collagen VII at the DEJ compared to BM-MSC injected in the same xenograft RDEB model. These data open the perspective of using gene-corrected BM-MSC from a Col7a1-/- RDEB murine model to restore normal dermal-epidermal adhesion. Col7a1-/- mice reproduce cutaneous and mucosal lesions observed in RDEB patients. The life expectancy of these animals is very short. We could show that transduction of Col7a1-/- murine BM-MSC in culture using a COL7A1-expressing SIN retroviral vector led to type VII collagen expression levels which were 30-fold higher on average than in BM-MSC from WT mice. In vivo data are required to determine whether the injection of gene-corrected BM-MSC has the potential to treat skin and mucosal lesions in RDEB mice and to define the optimal dose and duration of the effect in vivo. Restoration of type VII collagen expression and anchoring fibrils formation in Col7a1-/- mice would represent an important step towards clinical translation
APA, Harvard, Vancouver, ISO, and other styles
5

Lee, Nigel. "Comparison of a single versus a four intradermal sterile water injection technique for the relief of lower back pain for women in labour: A mixed methods study." Thesis, Australian Catholic University, 2013. https://acuresearchbank.acu.edu.au/download/fb8991208095920185a907088b92dba49532b490c2fcc90be0531a679c1ed24c/5032178/LEE_NIGEL_2013.pdf.

Full text
Abstract:
Significant back pain is often experienced by women in labour and may increase the need for pharmacological pain relief, often with associated side effects including excessive sedation and restriction to mobility. Sterile water injections (SWIs) are a simple, safe, effective, non-pharmacological technique for relieving back pain in labour; however, the number of injections required to achieve optimal analgesia is unknown. Furthermore, administration of SWI causes a brief, but intense, pain which may influence the acceptability of the procedure to labouring women. There is limited data from previous trials on how women view SWI, and the benefits of this particular analgesic option, versus the pain associated with administration. No previous studies have examined how midwives regard the prospect of causing pain to labouring women; albeit to relieve pain. The aim of this research was to determine if a single injection of sterile water was clinically similar to four injections in terms of degree of analgesia and to examine the experiences of labouring women and midwives receiving, and administering, SWIs...
APA, Harvard, Vancouver, ISO, and other styles
6

Kannanayakal, Thomas Joseph. "Inflammatory Cytokines in Jet Propulsion Fuel-8 Induced Irritant Contact Dermatitis in Male Fischer Rats." Wright State University / OhioLINK, 2009. http://rave.ohiolink.edu/etdc/view?acc_num=wright1242168249.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Lahm, Katja. "Investigation on intradermal delivery of drug powder by needle-free injection /." 2005. http://www.gbv.de/dms/bs/toc/501260501.pdf.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Intradermal Injections"

1

Eriksen, Stephanie. Intradermal injections. Irvine, CA: Distributed by Concept Media, 2005.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

DeCarlo, Ellen. Self-injection of gamma interferon. [Bethesda, Md.?]: Clinical Center Communications, National Institutes of Health, 1989.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

DeCarlo, Ellen. Self-injection of gamma interferon. [Bethesda, Md.?]: Clinical Center Communications, National Institutes of Health, 1989.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

DeCarlo, Ellen. Self-injection of gamma interferon. [Bethesda, Md.?]: Clinical Center Communications, National Institutes of Health, 1989.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

DeCarlo, Ellen. Self-injection of gamma interferon. [Bethesda, Md.?]: Clinical Center Communications, National Institutes of Health, 1989.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

DeCarlo, Ellen. Self-injection of gamma interferon. [Bethesda, Md.?]: Clinical Center Communications, National Institutes of Health, 1989.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Donnelly, Ryan F., and Thakur Raghu Raj Singh. Novel delivery systems for transdermal and intradermal drug delivery. Chichester, United Kingdom: John Wiley and Sons, Inc., 2015.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Sattler, G. (Gerhard), 1955- author, ed. Illustrated guide to aesthetic botulinum toxic injections: Basics, indications, uses. London: Quintessence, 2013.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Zwerling, Charles S. Micropigmentation: State of the art. [S.l.]: C.S. Zwerling, 1993.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

H, Christensen Frank, and Goldstein Norman, eds. Micropigmentation. Thorofare, NJ: Slack, 1986.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Intradermal Injections"

1

Seo, Kyle K. "Multiple Intradermal Botulinum Toxin Injections." In Botulinum Toxin for Asians, 135–39. Singapore: Springer Singapore, 2016. http://dx.doi.org/10.1007/978-981-10-0204-5_4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Yamamoto, Toshiyuki. "Intradermal Injections of Bleomycin to Model Skin Fibrosis." In Fibrosis, 43–47. New York, NY: Springer New York, 2017. http://dx.doi.org/10.1007/978-1-4939-7113-8_3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Jones, Meredyth L. "Injections-Subcutaneous (SC), Intramuscular (IM), Intradermal (ID), Intravenous (IV)." In Veterinary Techniques for Llamas and Alpacas, 29–32. Oxford, UK: Wiley-Blackwell, 2013. http://dx.doi.org/10.1002/9781118695111.ch6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Ganier, Clarisse, and Sonia Gaucher. "Emerging Technologies in Scar Management: The Role of Allogeneic Cells." In Textbook on Scar Management, 451–55. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-44766-3_51.

Full text
Abstract:
AbstractScars caused by burns, chronic ulcers from diabetes, infections, skin cancer surgery, and other genetic or somatic disease could require effective treatment to avoid functional and psychological troubles and even mortality. Most of the current treatments aim to reduce local inflammation but not to prevent scarring. Herein, we discussed about emerging technologies in scar management using allogeneic cell therapy. The industrialised allogeneic cell therapy products and the clinical trials using keratinocytes, fibroblasts or MSCs demonstrated acceleration of skin cell migration and proliferation, control wound scarring, immunomodulatory properties and improved angiogenesis. In addition, allogeneic cell transplants offered the possibility of large pre-fabrication, cryo-preservation, for instantaneous use and repeated applications. Current research exploring allogeneic cell therapies for scar treatment are focusing on grafting of epidermal sheets, cellular dermal substitutes and reconstructed skin equivalent and cell intradermal injections. Advances in knowledge in therapeutic potentials of allogeneic injected cells give rise to new therapeutic approaches such as administration of allogeneic cell-derived extracellular vesicles.
APA, Harvard, Vancouver, ISO, and other styles
5

Pascual, Thomas Neil, Pietro Zucchetta, Kevin London, and Robert Howman-Giles. "Lymphoscintigraphy." In A Practical Guide for Pediatric Nuclear Medicine, 157–66. Berlin, Heidelberg: Springer Berlin Heidelberg, 2023. http://dx.doi.org/10.1007/978-3-662-67631-8_9.

Full text
Abstract:
AbstractThis study evaluates lymphatic transit and lymph node accumulation of radiolabeled nanocolloids that, following intradermal injection, are cleared by the lymphatic system. Lymphoscintigraphy is also a sensitive, noninvasive method for evaluating lymphedema and the overall integrity of the lymphatic system.
APA, Harvard, Vancouver, ISO, and other styles
6

Heyer, G., and W. Magerl. "Skin Reactions and Sensations Induced by Intradermal Injection of Substance P into Compound 48/80 Pretreated Skin." In Wound Healing and Skin Physiology, 335–44. Berlin, Heidelberg: Springer Berlin Heidelberg, 1995. http://dx.doi.org/10.1007/978-3-642-77882-7_31.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

"Frey's Syndrome." In Diagnostic Techniques and Therapeutic Strategies for Parotid Gland Disorders, 296–323. IGI Global, 2021. http://dx.doi.org/10.4018/978-1-7998-5603-0.ch017.

Full text
Abstract:
Frey's syndrome is secondary to sympathetic denervation of sweat glands – reinnervation through the auriculotemporal nerve is a secondary event. The aberrant regeneration theory explains the physiopathology of Frey's syndrome. Frey's syndrome incidence after parotidectomy, without prevention techniques, is 40-80% by clinical questioning and 80–100% by objective testing. It occurs months to years after surgery. A topographic and quantitative testing for Frey's is required prior to its treatment – the iodine-sublimated paper histogram (ISPH) test has the majority of desired features. Intradermic botulinum toxin injection is a well-tolerated and efficient treatment. The recommended dilution is 50 IU/1 ml, inter-injection distance is 1 cm, and injection volume is 0.1 ml. Complications to avoid include (1) facial muscle paralysis (rare and reversible complication; inject only intradermally and avoid injecting toward the midline) and (2) pain during injection (if bothersome could be decreased by the prior application of topical anesthetic cream).
APA, Harvard, Vancouver, ISO, and other styles
8

Reza Namazi, Mohammad. "Intradermal Triamcinolone Injection." In Textbook of Advanced Dermatology: Pearls for Academia and Skin Clinics (Part 1), 29–30. BENTHAM SCIENCE PUBLISHERS, 2024. http://dx.doi.org/10.2174/9789815223521124010016.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

"Station 6 Intramuscular, subcutaneous, and intradermal injection techniques." In Clinical Skills for OSCEs, 31–33. CRC Press, 2006. http://dx.doi.org/10.1201/b17661-13.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Jong, Elaine C. "Immunizations." In Schlossberg's Clinical Infectious Disease, edited by Cheston B. Cunha, 761–80. Oxford University Press, 2021. http://dx.doi.org/10.1093/med/9780190888367.003.0113.

Full text
Abstract:
This chapter examines the long-lasting immunity against many serious infectious diseases that can be elicited through active immunization by the administration of specific antigens that stimulate the recipient host's production of protective antibodies. Protective levels of specific antibodies usually develop within 2 to 4 weeks after completion of the primary immunization regimen. The vaccine doses may be given orally, administered as mucosal vaccines, or given by injection using intradermal, subcutaneous, or intramuscular routes. The chapter also discusses passive immunization as the process by which protective immunity is obtained through transfer of preformed antibodies from an immune host to a nonimmune recipient, either as immunoglobulin or antibody-specific immunoglobulin. The chapter highlights host factors that influence protective efficacy resulting from active immunization. Vaccines used for recommended immunization coverage of children, adolescents, and adults are reviewed, along with relevant contraindications.
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Intradermal Injections"

1

Griebel, Adam, Tyler Novak, Kent D. Butz, Kevin Harris, Amy Kornokovich, Michael Chiappetta, and Corey P. Neu. "Prestress as an Optimal Biomechanical Parameter for Needle Penetration and Formulation Injection." In ASME 2011 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2011. http://dx.doi.org/10.1115/sbc2011-53202.

Full text
Abstract:
Intradermal and subcutaneous needle injections have long been used as a means to deliver vital medication subcutaneously across a range of applications from vaccines to insulin [1]. In order to optimize the efficacy of these injections, the needle must penetrate precisely to a targeted depth. However, the actual net penetration of the needle beneath the surface of the skin is confounded by the deflection of the skin. With the rise of the use of auto-injectors in such fields as diabetes care, achieving the actual required penetration becomes exceedingly important. There have been previous attempts to characterize this deflection [2–4], but these were limited in that they did not account for a range of factors that play a role in the penetration mechanics, and many were based on mathematical models, synthetic skin substitutes, or other tissues. The purpose of our work was to investigate the multiple factors that govern needle penetration and injection, including velocity, needle gauge, depth of insertion, and skin prestress.
APA, Harvard, Vancouver, ISO, and other styles
2

Lioce, Lori. "Development of a Needle Injection Pad Trainer for Simulating Intradermal, Subcutaneous and Intramuscular Injections: Used in Student Nurse Training." In The 33rd European Modeling & Simulation Symposium. CAL-TEK srl, 2021. http://dx.doi.org/10.46354/i3m.2021.emss.035.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Bedina Zavec, Apolonija. "Extracellular Vesicles for Cosmetic Applications." In Socratic Lectures 8. University of Lubljana Press, 2023. http://dx.doi.org/10.55295/psl.2023.ii16.

Full text
Abstract:
Extracellular vesicles (EVs) are nanosized membrane vesicles that carry membrane and cargo molecules inherited from their parental cells. Excellent delivery capacity, biological origin, and nanosized dimensions support the great potential of EVs as medical and cosmetic active ingredients. Many studies have already reported improved skin conditions by using EVs for skin rejuvenation, scar removal, and anti-pigmentation treatments. In this review, EVs from mesenchymal stem cells, platelets, skin microbiota, and microalgae will be considered. The most promising results come from mesenchymal stem cell (MSC) derived EVs that have impressive antiaging and wound-healing effects on the skin, but their use for medical or cosmetic purposes is not yet allowed in Europe and the United States. Autologous platelet- and extracellular vesicle-rich plasma (PVRP) is well tolerated and capable of rejuvenating the face; intradermal injections and topical applications are currently being considered in clinical and cosmetic dermatology. Symbiotic microorganisms of the human skin have many beneficial effects on the skin, but the presence of bacteria in cosmetic products is restricted; therefore, the preparation of EVs from skin-beneficial microbes is particularly relevant, and there are already many cosmetic products containing lysates from different probiotics on the market. Microalgae can produce many valuable bioactive compounds, antioxidants such as carotenoids are particularly interesting; therefore, microalgae are promising producers of EVs that could be used in cosmetic products. Keywords: Extracellular vesicles; Skin health; Microbiota; Mesenchymal stem cells; Micro-algae
APA, Harvard, Vancouver, ISO, and other styles
4

Williams, T. J., M. Rampart, S. Nourshargh, P. G. Hellewell, S. D. Brain, and P. J. Jose. "INTERACTION OF POLYMORPHONUCLEAR LEUKOCYTES AND ENDOTHELIAL CELLS : FUNCTIONAL CONSEQUENCES." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643985.

Full text
Abstract:
The mechanisms involved in the accumulation of polymorphonuclear leukocytes (PMNs) in an inflammatory reaction are complex. A key phase in this process is the attachment of the PMN to the microvascular (venular in most tissues) endothelial cell, initiated by the extravascular generation of a chemical mediator. Experiments in vitro suggest that mediators, such as C5a, may act in vivo by stimulating the increased expression of the CD18 complex on the surface of the PMN within the venule lumen (1), whereas IL-1 may act by causing the expression of an adhesive molecule on the endothelial cell (2). In vitro the former process is rapid whereas the latter is slow in onset. We have measured the local accumulation of intravenously-injected Ulln-PMNs in response to intradermally-injected mediators in the rabbit, in order to investigate possible mechanisms in vivo. PMN accumulation was found to be rapid in onset in response to C5a, the rate of accumulation falling progressively to low levels by 4 hours. In contrast PMN accumulation in response to IL-1 was slow in onset, reaching a peak rate at 3-4 hours. Intradermal injection of the vasodilator prostaglandins PGI2; PGE2 and the neuropeptides VIP and CGRP caused a marked potentiation of the rate of leukocyte accumulation. PMN accumulation induced by C5a was associated with increased microvascular permeability, as indicated by the leakage of intravenously-injected 125I-albumin with a time-course in parallel with the rate of PMN accumulation enhanced by intradermally-injected vasodilators. Depletion of circulating PMNs abolishes these responses to C5a (3). In contrast, leukocyte accumulation induced by IL-1 was associated with little plasma protein leakage, even in the presence of intradermal vasodilators. This observation indicates that PMN emigration itself does not lead to increased microvascular permeability. C5a, but not IL-1, may stimulate emigrating PMNs to secrete an endogenous factor that increases permeability by an action on endothelial cells (3). This factor does not appear to be the phospholipid PAF (4). In contrast to the enhancing effects of local PGI2, intravenously-infused PGI2 inhibited PMN accumulation induced by C5a and IL-1, and plasma protein leakage induced by C5a (5). This effect is probably mediated by elevation of cyclic AMP in intravascular PMNs. We have shown that C5a stimulation of PMNs in contact with endothelial cells in vitro induces endothelial cell PGI2 secretion (6). Thus, PGI2 may be part of a negative feedback system in vivo to control interactions between PMNs and endothelial cells.These observations provide some clues to the intricacies of mechanisms of leukocyte accumulation in vivo.
APA, Harvard, Vancouver, ISO, and other styles
5

Stolnitz, Mikhail M., Alexey N. Bashkatov, Elina A. Genina, and Valery V. Tuchin. "Mathematical modeling of clearing liquid drop diffusion after intradermal injection." In SPIE Proceedings, edited by Valery V. Tuchin. SPIE, 2007. http://dx.doi.org/10.1117/12.741083.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Liu, John, N. C. Hogan, and I. W. Hunter. "Intradermal needle-free powdered drug injection by a helium-powered device." In 2012 34th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC). IEEE, 2012. http://dx.doi.org/10.1109/embc.2012.6346366.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Konyakhina, Yu V., A. A. Sergeev, K. A. Titova, S. A. Pyankov, S. N. Yakubitskiy, and S. N. Shchelkunov. "LOW-DOSE SMALLPOX VACCINATION IN A MOUSE MODEL." In X Международная конференция молодых ученых: биоинформатиков, биотехнологов, биофизиков, вирусологов и молекулярных биологов — 2023. Novosibirsk State University, 2023. http://dx.doi.org/10.25205/978-5-4437-1526-1-254.

Full text
Abstract:
Vaccinia virus (VACV) strains caused a more pronounced production of antibodies with intradermal (i.d.) injection compared to scarification (s.s.) inoculation. To test for developed protective immunity at 62 day post vaccination (dpv), mice were intranasally infected with a cowpox virus. The results showed that i.d. injection provided the development of protective immunity in mice to a much greater extent compared to s.s. inoculation with VACV strains.
APA, Harvard, Vancouver, ISO, and other styles
8

Iradukunda, Lahai Rois, Omowunmi Isafiade, Meghann Petersen, Kessel Okinga Koumou, and Jeffrey Hoffman. "An Immersive Solution to Enhance Nursing Student Skills of Intradermal Injection on New-born." In 2024 IST-Africa Conference (IST-Africa). IEEE, 2024. http://dx.doi.org/10.23919/ist-africa63983.2024.10569645.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Md Yusof, Md Yuzaiful, Miriam Wittmann, Catherine Fernandez, Duncan Wilson, Sara Edward, Giuseppina Abignano, Adewonuola Alase, et al. "47 Targeted therapy using intradermal injection of etanercept for remission induction in discoid lupus erythematosus (TARGET-DLE): results from a proof-of-concept phase II trial." In 13th International Congress on Systemic Lupus Erythematosus (LUPUS 2019), San Francisco, California, USA, April 5–8, 2019, Abstract Presentations. Lupus Foundation of America, 2019. http://dx.doi.org/10.1136/lupus-2019-lsm.47.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Vledder, Annege, Hester Van Zeeburg, Satwinder Singh, Jeroen Rovers, Marco de Bruyn, and Hans Nijman. "672 Induction of specific T-cell responses to tumor associated antigens and induction of B-cell responses in ovarian cancer patients by intradermal injection of vididencel." In SITC 38th Annual Meeting (SITC 2023) Abstracts. BMJ Publishing Group Ltd, 2023. http://dx.doi.org/10.1136/jitc-2023-sitc2023.0672.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Intradermal Injections' for particular source types:
Journal articles Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography